Search - tctmd.com

Displaying 21 - 40 of 47

Sort: Relevancy | Date

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

News Conference News ESC 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

September 01, 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

September 01, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

August 29, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

June 02, 2017

TCTMD’s Top 10 Most Popular Stories for May 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

June 01, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

May 22, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.